
Hiroshi Yoshida

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9709807/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Current concept and residual issues of lipoprotein(a) determination for a cardiovascular risk factor. European Journal of Clinical Investigation, 2022, 52, e13700.	3.4	3
2	Research on Functional Nutrients and Lipoprotein Quality Evaluation Contributing to a Reduction in Risk Factors for Atherosclerosis. Nihon EiyŕShokuryŕGakkai Shi = Nippon EiyŕShokuryŕGakkaishi = Journal of Japanese Society of Nutrition and Food Science, 2022, 75, 3-10.	0.2	0
3	Verification of Low-Density Lipoprotein Cholesterol Levels Measured by Anion-Exchange High-Performance Liquid Chromatography in Comparison with Beta Quantification Reference Measurement Procedure. journal of applied laboratory medicine, The, 2021, 6, 654-667.	1.3	3
4	Secondary dyslipidemia: its treatments and association with atherosclerosis. Global Health & Medicine, 2021, 3, 15-23.	1.4	24
5	A new method for measuring cholesterol efflux capacity uses stable isotope-labeled, not radioactive-labeled, cholesterol. Journal of Lipid Research, 2019, 60, 1959-1967.	4.2	8
6	Innovatively Established Analysis Method for Lipoprotein Profiles Based on High-Performance Anion-Exchange Liquid Chromatography. Journal of Atherosclerosis and Thrombosis, 2019, 26, 1027-1040.	2.0	13
7	Beneficial Effects of Adiponectin on Glucose and Lipid Metabolism and Atherosclerotic Progression: Mechanisms and Perspectives. International Journal of Molecular Sciences, 2019, 20, 1190.	4.1	282
8	Clinical Impact and Significance of Serum Lipoprotein (a) Levels on Cardiovascular Risk in Patients With Coronary Artery Disease. Circulation Journal, 2019, 83, 967-968.	1.6	4
9	Diabetic dyslipidemia: evaluation and mechanism. Global Health & Medicine, 2019, 1, 30-35.	1.4	15
10	Age and sex differences in serum adiponectin and its association with lipoprotein fractions. Annals of Clinical Biochemistry, 2018, 55, 165-171.	1.6	19
11	1069. Predictive Factors for Metastatic Infection in Patients With Bacteremia Caused by Staphylococcus aureus. Open Forum Infectious Diseases, 2018, 5, S320-S320.	0.9	1
12	Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017. Journal of Atherosclerosis and Thrombosis, 2018, 25, 846-984.	2.0	541
13	An Intriguing and Important Concept Relevant to Oxidized Low-Density Lipoprotein and Atherogenesis is Still Problematic for its Contribution to the Better Understanding of Clinical Atherosclerosis. Journal of Atherosclerosis and Thrombosis, 2018, 25, 1007-1008.	2.0	0
14	A First-in-Class Drug, Lomitapide, Tailored to Patients with Homozygous Familial Hypercholesterolemia is Just about Meeting with Good News to Them. Journal of Atherosclerosis and Thrombosis, 2017, 24, 390-392.	2.0	5
15	Determination of Fasting and Non-Fasting Cholesterol Levels of Low- and High-Density Lipoproteins with Homogenous Assays: A Promising Reliable Way to Assessment of Dyslipidemia. Journal of Atherosclerosis and Thrombosis, 2017, 24, 569-571.	2.0	4
16	Potential Anti-Atherosclerotic Properties of Astaxanthin. Marine Drugs, 2016, 14, 35.	4.6	157
17	Monthly PCSK9 inhibitors: The CHOICE for prolonged duration of effect. Atherosclerosis, 2016, 254, 300-302.	0.8	1
18	Understanding of Diabetic Dyslipidemia by Using the Anion-Exchange High Performance Liquid Chromatography Data. Journal of Clinical Medicine Research, 2016, 8, 424-426.	1.2	10

Hiroshi Yoshida

#	Article	IF	CITATIONS
19	Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes. Atherosclerosis, 2015, 241, 409-418.	0.8	87
20	Clinical relevance of decreased ratios of serum eicosapentaenoic acid/arachidonic acid (AA) and docosahexaenoic acid/AA to impaired arterial stiffness. International Journal of Cardiology, 2014, 177, 517-519.	1.7	7
21	Relevance of intermediate-density lipoprotein cholesterol to Framingham risk score of coronary heart disease in middle-aged men with increased non-HDL cholesterol. International Journal of Cardiology, 2013, 168, 3853-3858.	1.7	23
22	Effects of pitavastatin and atorvastatin on lipoprotein oxidation biomarkers in patients with dyslipidemia. Atherosclerosis, 2013, 226, 161-164.	0.8	41
23	Estimation of lipoprotein profile in patients with type II diabetes and its relevance to remnant lipoprotein cholesterol levels. Atherosclerosis, 2012, 222, 541-544.	0.8	11
24	Gender Differences in the Effects of Angiotensin Receptor Blockers on Cardiovascular Disease. Current Pharmaceutical Design, 2011, 17, 1090-1094.	1.9	10
25	Sex differences in effects of valsartan administration on cardiovascular outcomes in hypertensive patients: findings from the Jikei Heart Study: Retracted. Journal of Hypertension, 2010, 28, 1150-1157.	0.5	7
26	Acute progression of congestive heart failure during paroxysmal supraventricular tachycardia in a patient without structural heart disease. Journal of Cardiology Cases, 2010, 1, e133-e136.	0.5	2
27	Effects of Supervised Aerobic Exercise Training on Serum Adiponectin and Parameters of Lipid and Glucose Metabolism in Subjects with Moderate Dyslipidemia. Journal of Atherosclerosis and Thrombosis, 2010, 17, 1160-1166.	2.0	40
28	Analysis of cholesterol levels in lipoprotein(a) with anion-exchange chromatography. Journal of Lipid Research, 2010, 51, 1237-1243.	4.2	13
29	Mechanisms of LDL oxidation. Clinica Chimica Acta, 2010, 411, 1875-1882.	1.1	229
30	Administration of natural astaxanthin increases serum HDL-cholesterol and adiponectin in subjects with mild hyperlipidemia. Atherosclerosis, 2010, 209, 520-523.	0.8	203
31	Measurement of cholesterol concentrations of major serum lipoprotein classes in haemodialysis patients by anion-exchange chromatography. Annals of Clinical Biochemistry, 2008, 45, 571-574.	1.6	16
32	Characteristic comparison of triglyceride-rich remnant lipoprotein measurement between a new homogenous assay (RemL-C) and a conventional immunoseparation method (RLP-C). Lipids in Health and Disease, 2008, 7, 18.	3.0	18
33	Antihypertensive effects of astaxanthin. Integrated Blood Pressure Control, 2008, Volume 1, 1-3.	1.2	7
34	Comparative study between anion-exchange HPLC and homogeneous assay methods in regard to the accuracy of high- and low-density lipoprotein cholesterol measurement. Clinical Biochemistry, 2007, 40, 1291-1296.	1.9	10
35	Neuroprotective Effects of Edaravone: a Novel Free Radical Scavenger in Cerebrovascular Injury. CNS Neuroscience & Therapeutics, 2006, 12, 9-20.	4.0	324
36	Implications of decreased serum adiponectin for type IIb hyperlipidaemia and increased cholesterol levels of very-low-density lipoprotein in type II diabetic patients. Clinical Science, 2005, 109, 297-302.	4.3	16

Hiroshi Yoshida

#	Article	IF	CITATIONS
37	Edaravone, a novel radical scavenger, inhibits oxidative modification of low-density lipoprotein (LDL) and reverses oxidized LDL-mediated reduction in the expression of endothelial nitric oxide synthase. Atherosclerosis, 2005, 179, 97-102.	0.8	59
38	Effects of simvastatin 20 mg/d on serum lipid profiles in Japanese hyperlipidemic patients: A prospective, open-label pilot study. Current Therapeutic Research, 2005, 66, 613-629.	1.2	3
39	Increased serum iron may contribute to enhanced oxidation of low-density lipoprotein in smokers in part through changes in lipoxygenase and catalase. Clinica Chimica Acta, 2004, 345, 161-161.	1.1	0
40	Increased serum iron may contribute to enhanced oxidation of low-density lipoprotein in smokers in part through changes in lipoxygenase and catalase. Clinica Chimica Acta, 2004, 345, 161-170.	1.1	29
41	Measurement of cholesterol of major serum lipoprotein classes by anion-exchange HPLC with perchlorate ion-containing eluent. Journal of Lipid Research, 2003, 44, 1404-1412.	4.2	55
42	Sweet Elements of Siraitia Grosvenori Inhibit Oxidative Modification of Low-Density Lipoprotein Journal of Atherosclerosis and Thrombosis, 2002, 9, 114-120.	2.0	41
43	Inhibitory effect of tea flavonoids on the ability of cells to oxidize low density lipoprotein. Biochemical Pharmacology, 1999, 58, 1695-1703.	4.4	116
44	Beneficial effect of gemfibrozil on the chemical composition and oxidative susceptibility of low density lipoprotein: a randomized, double-blind, placebo-controlled study. Atherosclerosis, 1998, 139, 179-187.	0.8	35
45	Minimally Oxidized Low-Density Lipoprotein Increases Expression of Scavenger Receptor A, CD36, and Macrosialin in Resident Mouse Peritoneal Macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 794-802.	2.4	152
46	Identification of the lectin-like receptor for oxidized low-density lipoprotein in human macrophages and its potential role as a scavenger receptor. Biochemical Journal, 1998, 334, 9-13.	3.7	230
47	Vitamin E/Lipid Peroxide Ratio and Susceptibility of LDL to Oxidative Modification in Non–Insulin-Dependent Diabetes Mellitus. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17,	2.4	47